-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Metastatic breast cancer (mBC) is an incurable disease.
The median 5-year overall survival (OS) of patients suffering from this disease is only 25%.
Currently, HER2 therapy and endocrine therapy are the first-choice therapies for HER2+ and HR+ tumors, respectively.
However, for patients with ER/PR+ who are resistant to endocrine therapy or with critical symptoms of organ metastasis and TNBC (triple-negative breast cancer), chemotherapy (mainly anthracyclines and taxanes) is still the recommended therapy.
The median 5-year overall survival (OS) of patients suffering from this disease is only 25%.
At present, HER2 therapy and endocrine therapy are the first-choice therapies for HER2+ and HR+ tumors, respectively.
Metastatic breast cancer (mBC) is an incurable disease.
The median 5-year overall survival (OS) of patients suffering from this disease is only 25%.
At present, HER2 therapy and endocrine therapy are the first-choice therapies for HER2+ and HR+ tumors, respectively.
Breast cancer
Eribulin is a microtubule-targeted drug (MTA) that has been approved for the treatment of advanced or metastatic breast cancer patients with previous treatment regimens based on anthracycline and taxane drugs.
It can significantly improve the patient's OS.
It can significantly improve the patient's OS.
Eribulin is a microtubule-targeted drug (MTA) that has been approved for the treatment of advanced or metastatic breast cancer patients with previous treatment regimens based on anthracycline and taxane drugs.
It can significantly improve the patient's OS.
Previous studies have shown that PIK3CA mutations are associated with adverse reactions to chemotherapy in patients with ER+/HER2-metastatic BC.
This study aims to evaluate the role of mutations in the PI3K/AKT signaling pathway in eribulin resistance.
Researchers evaluated the drug resistance of eribulin in the HER2-BC cell line and patient-derived xenografts, and studied its correlation with mutations in the PI3K/AKT signaling pathway.
Inhibition of PI3K can increase the activity of eribulin
The results showed that among 23 patients with HER2-BC transplanted tumors treated with eribulin, 11 showed disease progression.
No correlation with ER status was detected.
Researchers have observed that eribulin treatment can induce phosphorylation of AKT.
Similarly, regardless of the mutation status of the PI3K/AKT signaling pathway and the status of the ER, PI3K inhibitors can reverse the generation of primary and acquired resistance of eribulin in xenograft tumor models.
Inhibition of PI3K can reverse the resistance of eribulin treatment and restore the treatment response
In summary, the results of the study reveal that the activation of the PI3K signaling pathway can induce the generation of primary resistance to eribulin.
Therefore, the combination therapy of PI3K inhibitors and eribulin may become a potential treatment strategy for patients with HER2-BC.
The activation of the PI3K signaling pathway can induce the generation of primary resistance to eribulin.
org/10.
Leave a message here
